Clinical TrialAug 3, 2026, 08:03 AM
Akebia Initiates Phase 2 Trial for Ebribafusp in Kidney Diseases
AI Summary
Akebia Therapeutics announced the initiation of a Phase 2 basket trial for ebribafusp, an anti-C3d factor H fusion protein, to evaluate its safety, efficacy, and pharmacokinetics in rare complement-mediated kidney diseases. The trial will target IgA nephropathy, lupus nephritis, and C3 glomerulopathy, enrolling up to 30 patients. Ebribafusp is designed to inhibit complement activation in tissues without affecting the complement system in the blood, potentially offering a safer treatment option. Initial data from the trial is anticipated in 2027.
Key Highlights
- Initiated Phase 2 basket trial for ebribafusp in rare kidney diseases.
- Ebribafusp targets IgA nephropathy, lupus nephritis, and C3 glomerulopathy.
- Trial aims to enroll up to 30 patients for 26 weeks of subcutaneous dosing.
- Primary endpoint is the incidence of adverse events.
- Secondary endpoints include changes in proteinuria and kidney function.
- Initial data from the Phase 2 trial is expected in 2027.
- Akebia acquired global rights to ebribafusp from Q32 Bio in November 2025.
Price Impact
More from AKBA